Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02574455
Title ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.

triple-receptor negative breast cancer


Sacituzumab govitecan-hziy

Capecitabine + Eribulin + Gemcitabine + Vinorelbine

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.